These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22693229)

  • 1. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Qin M; Levin MJ; Fenton T; Beeler JA; Bellini WJ; Audet S; Sowers SB; Borkowsky W; Nachman SA; Pelton SI; Rosenblatt HM;
    J Infect Dis; 2012 Aug; 206(4):512-22. PubMed ID: 22693229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.
    Chandwani S; Beeler J; Li H; Audet S; Smith B; Moye J; Nalin D; Krasinski K;
    J Infect Dis; 2011 Jul; 204 Suppl 1(Suppl 1):S179-89. PubMed ID: 21666159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.
    Rainwater-Lovett K; Nkamba HC; Mubiana-Mbewe M; Bolton-Moore C; Moss WJ
    J Infect Dis; 2013 Dec; 208(11):1747-55. PubMed ID: 23911708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre- and post-highly active antiretroviral therapy and revaccination.
    Farquhar C; Wamalwa D; Selig S; John-Stewart G; Mabuka J; Majiwa M; Sutton W; Haigwood N; Wariua G; Lohman-Payne B
    Pediatr Infect Dis J; 2009 Apr; 28(4):295-9. PubMed ID: 19258919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to Measles, Mumps, and Rubella in US Children With Perinatal HIV Infection or Perinatal HIV Exposure Without Infection.
    Siberry GK; Patel K; Bellini WJ; Karalius B; Purswani MU; Burchett SK; Meyer WA; Sowers SB; Ellis A; Van Dyke RB; ;
    Clin Infect Dis; 2015 Sep; 61(6):988-95. PubMed ID: 26060291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children.
    Berkelhamer S; Borock E; Elsen C; Englund J; Johnson D
    Clin Infect Dis; 2001 Apr; 32(7):1090-4. PubMed ID: 11264038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Responses to Measles Revaccination at 24 Months in HIV-infected Children on Antiretroviral Therapy in Kenya.
    Newman LP; Njoroge A; Magaret A; Chohan BH; Gitomea VW; Wald A; Gorstein J; Overbaugh J; Wamalwa D; Maleche-Obimbo E; Nduati R; Farquhar C
    Pediatr Infect Dis J; 2017 Dec; 36(12):1148-1155. PubMed ID: 28198789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Warshaw M; Rosenblatt HM; Levin MJ; Nachman SA; Pelton SI; Borkowsky W; Fenton T;
    J Infect Dis; 2009 Sep; 200(6):935-46. PubMed ID: 19663708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy.
    Lao-Araya M; Puthanakit T; Aurpibul L; Taecharoenkul S; Sirisanthana T; Sirisanthana V
    Vaccine; 2011 May; 29(23):3977-81. PubMed ID: 21473954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2010 May; 50(10):1415-8. PubMed ID: 20377409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M; Kanra G; Erdem G; Kanra B
    Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Immune Response to Measles Component of MMR Vaccine in Children with HIV Infection Receiving Antiretroviral Therapy.
    Seth A; Deepa S; Dutta R; Chandra J
    Pediatr Infect Dis J; 2016 Jan; 35(1):e8-11. PubMed ID: 26418241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measles vaccine, HIV infection, and antiretroviral therapy--a window of opportunity.
    Maldonado Y
    J Infect Dis; 2012 Aug; 206(4):466-8. PubMed ID: 22693235
    [No Abstract]   [Full Text] [Related]  

  • 16. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection.
    Brunell PA; Vimal V; Sandu M; Courville TM; Daar E; Israele V
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):540-8. PubMed ID: 8548333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.
    Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ
    Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy.
    Melvin AJ; Mohan KM
    Pediatrics; 2003 Jun; 111(6 Pt 1):e641-4. PubMed ID: 12777579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
    Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
    Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults.
    Stermole BM; Grandits GA; Roediger MP; Clark BM; Ganesan A; Weintrob AC; Crum-Cianflone NF; Ferguson TM; Macalino GE; Landrum ML
    Vaccine; 2011 Apr; 29(16):2874-80. PubMed ID: 21352938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.